these insulins, along with advances in animal insulin purification, significantly decreased insulin allergy and lipoatrophy. However, these preparations did not fully mimic endogenous insulin secretion, and hypoglycemia remained a common adverse effect [2] .
Long-acting (basal) insulin analogs were developed to provide a more physiologic pharmacokinetic/pharmacodynamic (PK/PD) profile with longer duration, less intrapatient variability, less pronounced peak in time-action profiles, and decreased hypoglycemic risk compared with human insulins [3] . Although long-acting insulin analogs have improved PK/PD profiles and have reduced the safety concerns in patients with both type 1 and type 2 diabetes, up to 40% of patients still require twicedaily injections of long-acting insulin analogs, as the currently available basal insulins do not last 24 hours in some patients [3] [4] [5] . These patients in particular could benefit from insulin options with longer time-action profiles. In addition to long-acting insulin analogs, rapid-acting (bolus) insulin analogs were developed to fulfill a need for insulin with a faster onset and shorter duration than regular human insulin (RHI) [6] .
Together with long-acting insulin analogs, rapid-acting insulin analogs better simulate endogenous insulin secretion.
Further enhancements are still necessary to ensure optimal insulin treatment. A major goal of investigational insulins, including ultralong-acting, inhaled, and oral insulins, is to provide optimal insulin coverage that more closely mimics endogenous insulin secretion, while decreasing the risk of hypoglycemia and improving adherence. This will ultimately improve glycemic control and minimize complications. Inhaled and oral insulins also represent potential noninvasive routes of insulin administration, which could improve patient adherence [7] [8] [9] . This review will discuss the Although initial preparations of insulin from animal sources were successful in treating patients with diabetes, these early insulins had highly variable efficacy. Impurities in animal insulin products were associated with side effects such as insulin allergy and lipoatrophy, prompting researchers to develop methods for insulin purification [1] . Therefore, synthetic and recombinant "human" insulins were developed to enhance insulin purity as well as reproducibility of response. The production of were included and an assessment of the study design, methodology, clinical relevance, and impact on the evolution of insulin development was performed. In addition, the bibliographies of articles of interest were reviewed and key references were obtained. A total of 92 articles was selected and analyzed.
ANIMAL INSULIN

Reduction of Mortality, Adverse Events, and
Emergence of Hypoglycemia
Before the discovery of insulin, type 1 diabetes was a fatal disease due to the inevitable development of diabetic ketoacidosis in the late stages of the disease process [12] . At that time, the goal of treatment was limited to reducing mortality, with no caveats to reach that goal. Insulin treatment vastly increased the life expectancy of patients with diabetes and allowed them to meet treatment goals. However, glass syringes were used and the needles required sharpening before injection. This early insulin came from the purification of porcine or bovine pancreases [13] , and within a few years after its discovery, the limitations of animal insulin became increasingly apparent. Common adverse effects in early insulin treatment included insulin allergy, abscesses, lipodystrophy, and insulin antibody formation. These adverse effects were mainly related to the impurity and species specificity of the insulin preparations [1, 13] .
As insulin purification techniques improved, the duration of action of insulin decreased, and patients required multiple injections throughout the day to avoid severe glycosuria [12] . This often led to either poor patient adherence or alternating extremes of hyperglycemia and hypoglycemia resulting from the boluses of these shorter-acting formulations [12] . As concerns regarding hypoglycemia emerged as evolution of insulin development from early animal insulin to current investigational insulin, with a focus on limitations and how they were, or will be, overcome.
Because diabetes is a chronic condition, attention to patient lifestyle considerations is important in insulin development to better empower patients and improve adherence.
Indeed, more physiologic PK/PD parameters can facilitate adherence by allowing dosing times that better fit the daily schedules of patients.
Subcutaneous insulin administration presents a challenge for patients who fear the pain or inconvenience of injection [10] , something that has been and continues to be addressed by ongoing improvements in insulin pen devices and needles.
As insulin has evolved, so has the definition of a unit of insulin. The definition of one unit of insulin is, "the amount of insulin that will lower the blood glucose of a healthy 2 kg (4.4 lb) rabbit that has fasted for 24 hours to 2.5 mmol/L (45 mg/dL) within 5 hours" [11] .
LITERATURE SEARCH METHODOLOGY
Information for this narrative, nonsystematic review was gathered by reviewing clinical trial data. A PubMed literature search was conducted to identify relevant, peer-reviewed clinical and review articles published between 1980 and September 2011 related to the evolution of insulin development. Search terms included "animal insulin," "synthetic insulin," "regular human insulin," "insulin lispro," "insulin aspart," "insulin glulisine," "insulin glargine," "insulin detemir," "insulin degludec," "biphasic human insulin," "insulin premixes," "ultra-long acting insulin," "oral insulin," and "inhaled insulin." Case studies and editorials were excluded. Primary manuscripts and reviews an obstacle to effective treatment with insulin, encouraging patients to adhere to treatment regimens became a priority and the driving force behind further insulin development.
The first slow-release insulins using the animal protein protamine were developed in 1936. These insulins reduced, but did not eliminate, the incidence of hypoglycemic episodes [14] . The first slow-release insulin, neutral protamine Hagedorn (NPH), was an intermediate-acting complex of protamine, a protein isolated from fish sperm that reduced the solubility of insulin and zinc [12] .
NPH was originally made by combining protamine with animal insulin, but was later added to insulin that was produced using recombinant DNA technology. It is so named because NPH was developed in the Hagedorn Laboratory in Denmark by Nordisk in 1946 [15] .
Interestingly, NPH was considered a long-acting basal agent before the development of basal insulin analogs although its duration of action is only 12-18 hours [16, 17] . In addition, with NPH there is a shift in the peak with larger doses due to the depot effect, which, clinically, is a limiting factor [18] . A high level of hypoglycemia, particularly nocturnal hypoglycemia, was and still is one of the major limitations of NPH [19] .
While gains were made in patient convenience, the issue of hypoglycemia remained.
In the 1970s, the production of highly purified animal insulins reduced the insulin dose needed for diabetes control and partially prevented local reactions such as lipoatrophy [20] .
In one study, lipoatrophy was found in 49 of 511 (9.6%) patients with diabetes treated with conventional therapy, but not in those treated solely with very pure porcine insulin [20] .
However, in later studies, sporadic cases of lipoatrophy were reported with both highly purified porcine and bovine insulin, indicating that this side effect had not been completely eliminated [21] . Therefore, while the insulin purification process decreased the incidence of adverse events, further improvements were still necessary.
Variable Efficacy and Risk of Hypoglycemia with Animal Insulin
Large-scale production of insulin following its initial discovery was challenging, partly due to the temperature and pH variability between batches. A collaboration between Eli Lilly and the Toronto group of Banting, Best, Collip, Campbell, Fletcher, Macleod, and E.C.
Noble led to the production of more potent porcine insulin preparations in mid-1922 [13] .
However, the lot-to-lot potency still varied by 25%, so physicians had to be constantly on the lookout for signs of hypoglycemia from excessive insulin [13] . Eli Lilly and Company's chief chemist George Walden developed the isoelectric precipitation method to improve the stability and purity of insulin significantly [13] .
However, standardization problems persisted, with consistency from batch to batch still varying by 10% [13] .
Insulin Efficacy Criteria
Measurements of insulin efficacy have evolved along with the development of new insulins.
Before the introduction of hemoglobin A1c (HbA 1c ) in 1976 as a means of monitoring longterm blood glucose levels [22] , insulin efficacy was generally assessed using postprandial glucose (PPG) and fasting plasma glucose (FPG) levels. HbA 1c , the measure of circulating glycated hemoglobin over the previous 2-3-month period, has since become the standard for evaluating the success of diabetes treatment regimens [23] 
SYNTHETIC INSULINS
Synthetic insulins were developed to provide patients with diabetes a potentially more effective and more readily available alternative to animal insulins. Following the characterization of the amino acid structure of human insulin, synthetic insulin was produced in American, German, and Chinese laboratories in the 1960s [27] [28] [29] , making insulin the first protein ever synthesized in vitro [30] .
Synthetic insulin with the amino acid structure of human insulin is prepared using several techniques, including total chemical synthesis, semisynthesis, which involves substituting the alanine in porcine insulin with threonine, and recombinant DNA methods [31, 32] .
In the first clinical trial of insulin produced by total chemical synthesis (CGP 12831), six patients with diabetes showed evidence of full biologic action of the synthetic insulin [29] .
Ketoacidosis was corrected in one patient, and synthetic insulin normalized the hyperglycemia in a patient with poor response to oral antidiabetic drugs [29] . However, two patients experienced more sudden hypoglycemic events than with animal insulin [29] .
Another study investigating the safety and efficacy of semisynthetic human insulin in healthy patients found no difference in the potency, onset, and duration of effect between semisynthetic and porcine insulins [31] .
Furthermore, in a study of patients with type 1 diabetes, semisynthetic insulin also showed no significant differences in blood glucose control and subcutaneous absorption compared with porcine insulin [32] . Together, these data suggested that synthetic insulins were a more viable option for most patients with diabetes than animal insulins. However, hypoglycemia remained a significant concern.
REGULAR HUMAN INSULINS
Advances in Insulin Production but Still
Problems with Glycemic Control
The development of recombinant DNA technology finally allowed for the largescale synthesis of insulin. In 1978, scientists from Genentech used recombinant DNA technology to synthesize the A and B chains of insulin in Escherichia coli [33] . In vivo, insulin is synthesized from cleavage of a large polypeptide proinsulin that generates a C peptide and covalently links the A and B chains of insulin together (Fig. 1) [34, 35] .
However, when insulin is made in vitro with recombinant DNA technology, the A and B chains are synthesized separately using E. coli, and then joined together biochemically [33] .
In 1982, Eli Lilly and Company [36] developed a short-acting insulin called Humulin R [37] and an intermediate-acting NPH insulin called Humulin N [38] . Human insulin synthesized by recombinant DNA technology was first tested in 17 healthy male volunteers [39] , and it had similar glucose-lowering properties when compared to purified porcine insulin [39] .
Therefore, RHI appeared to be a good alternative to animal insulin. Novo Nordisk also started producing biosynthetic human insulin (BHI) in 1987 [40] .
Advances in insulin purity, species, and characteristics of the retarding agent were observed during the development of RHI [16] . (Fig. 2 [41] ) [17] , and there is considerable inter and intra-subject variation in bioavailability [16] , because NPH is a suspension that must be mixed before injection [16, 17] .
Even in clinical research centers, the variability of the glucose infusion rate approaches 68% using clamp data. Differences in the site of injection can lead to variability in the absorption of NPH [16] .
Furthermore, in a double-blind crossover trial, treatment with porcine or bovine insulin was compared with BHI in 94 patients with diabetes [42] . This was presumably due to the different pharmacokinetic properties of BHI. Consistent with this, previous evidence showed that BHI is absorbed, and likely excreted or inactivated, more quickly than purified porcine insulin in normal subjects. Patients' willingness to adhere to therapy can be greatly undermined by the dosing inconvenience of RHI and NPH and the potential hypoglycemic episodes because of the extended duration of effect with larger doses of NPH [18, 43] .
As RHI has a relatively slow onset, it needs to be administered 30-60 minutes before a meal, the time of which can be difficult to predict. Therefore, short-acting analogs that can be injected right before a meal were needed [16, 44] . 
INSULIN ANALOGS
Development of Insulin Analogs
By the early 1990s, great strides had been Insulin analogs were designed to provide either a basal or bolus option to stimulate normal insulin physiology and secretion more closely, 
to dimers, which are further resolved into the absorbable monomer form. Among bolus insulin types, substitutions in this region can aid rapid absorption [49] . These substitutions include the reversal of the natural sequences of proline at position B28 and lysine at position B29 in insulin lispro (Fig. 3b) , the natural sequences of proline at position B28 substituted by aspartic acid in insulin aspart ( and adding a myristic fatty acid residue to the ε-amino group of the lysine residue at B29 [50] .
The newer long-acting insulin analog degludec has an insulin amino acid sequence that matches human insulin except Thr B30 is deleted and a 16-carbon fatty diacid is attached to Lys B29 with a glutamic acid spacer ( Fig. 4c ) [50] . Insulin analog premixes have also been developed to minimize patient error when combining insulins and to provide basal and bolus coverage in one injection; however, premixes might not provide optimal glycemic control for all patients due to the fixed ratio of their components [48] .
PK/PD of Basal, Bolus, and Insulin Analog Premixes
Long-Acting Insulin Analogs More Closely Mimic Physiologic Basal Insulin Secretion
Basal analogs (Fig. 4 [50] ) were designed to provide consistent, flat, long-acting insulin levels to mimic the constant release of insulin that regulates endogenous glucose output [48] .
Two basal insulin analogs, insulin glargine and insulin detemir, are currently available [48] . In solution, insulin glargine has an acidic pH (pH 4) and upon subcutaneous injection the acidic solution becomes neutralized thereby forming microprecipitates. This contributes to the slow release of insulin glargine into the circulation [48] .
With insulin detemir, acylation of the molecule gives it a high binding affinity for albumin, which delays its absorption [50] . [57] .
At the two lower doses, the duration of action was estimated to be below 24 hours. The authors note that this pharmacokinetic study should not be extrapolated to clinical response [57] .
Furthermore, some healthcare providers split doses. On balance, true basal coverage for all patients has not yet been fully achieved [4] .
Rapid-Acting Insulin Analogs Add to Patient
Convenience
In response to the shortcomings of the PK/PD profiles of RHI, which include a slow onset of action, a peak effect 3 hours after dosing, and a duration of action beyond 8 hours, three rapidacting bolus insulin analogs have been developed to date: insulin glulisine, insulin lispro, and insulin aspart [58] . All three analogs have a rapid onset of action (within 30-60 minutes) and a peak action within 2 hours, compared with the onset of action of 45-60 minutes and peak effect of 3 hours after RHI dosing ( Fig. 2 [41] ) [6, 10, 58, 59 ].
Whereas RHI must be given more than 30 minutes before meals, rapid-acting insulin analogs can be given just before a meal or even after the meal has begun. In a study involving type 1 diabetes patients treated with basal-bolus therapy, patients assigned to insulin aspart as their bolus therapy indicated a greater degree of flexibility compared to patients using RHI [60] . The inconvenience of insulin administration plays a large part in nonadherence to insulin regimens [48] . Because they have a more convenient administration schedule, bolus insulin analogs may improve patient adherence to prescribed treatments.
Insulin lispro was the first rapid-acting bolus insulin analog developed. The inversion of the lysine of B29 and the proline of B28 of human insulin allows insulin lispro to dissociate rapidly into monomers and become quickly absorbed into the circulation [2] . As an alternative approach, the structure of insulin aspart prevents self-association into insulin dimers and hexamers, which increases the rate of absorption of the insulin monomers into the blood [49, 61] . For insulin glulisine, the amino acid alteration at positions B3 and B29 provides molecular stability and lowers the isoelectric point of insulin glulisine (pH 5.1) compared to RHI (pH 5.5), enhancing insulin glulisine's solubility at a physiologic pH [49, 62] . Unlike other bolus insulin analogs, insulin glulisine does not contain the hexamer-promoting zinc, allowing for immediate bioavailability at the injection site [49] .
Insulin lispro, insulin aspart, and insulin glulisine have similar PK/PD properties and show low intrasubject variability. In general, all rapid-acting analogs achieve twice the maximal concentration and take about half the time to reach maximal concentration compared to equivalent doses of RHI [6, 10, [63] [64] [65] . The faster and more intense action of the insulin analogs more closely mimics endogenous insulin response, which can lead to better control of PPG levels compared to RHI [6, 66] . In contrast to RHI, there is no delay in peak as the dose and depot increase. One study found that with a dose of 10 U of insulin lispro, the mean peak insulin action was 99 ± 39 minutes, as compared with 179 ± 93 minutes for RHI (P < 0.05) [10] . For insulin aspart, Mudaliar et al.
reported that the time to peak insulin action was 94 ± 46 minutes compared to 173 ± 62 minutes for RHI (P < 0.001) [6] . Another study found that in healthy subjects, insulin aspart was absorbed twice as quickly and reached more than double the serum concentrations compared to RHI [67] .
Also, both insulin glulisine and insulin lispro had more rapid-acting profiles than RHI in a study involving 18 subjects without diabetes [63] .
Insulin Analog Premixes
Insulin analog premixes are fixed-ratio [78] [79] [80] . This loss of warning symptoms obviates any opportunity for the patient to take corrective action [74] . Therefore, even minor hypoglycemic events may impair the ability of a patient to recognize the hypoglycemic symptoms. Reductions in hypoglycemia may be related in part to insulin detemir's reduced glycemic variability, or to the lack of an insulin peak when compared with NPH. Pieber et al. compared
once-daily insulin glargine and twice-daily insulin detemir in patients with type 1 diabetes and found that the overall risk of hypoglycemia was similar after the administration of either insulin [3] . However, the risks of both severe and nocturnal hypoglycemia were significantly lower with insulin detemir than with insulin glargine (72% and 32% reduction, respectively, P < 0.05).
Therefore, insulin detemir may be more effective in reducing nocturnal hypoglycemia than insulin glargine in patients with type 1 diabetes, but further studies are needed to clarify this. [97] .
Insulin Analog Premixes Reduce Hypoglycemia
Intrapatient daily variation in plasma glucose was also lower with insulin detemir/insulin aspart than with NPH/RHI [97] . Taken together, these results suggest that insulin glargine and insulin detemir are more effective for glycemic control than NPH.
Insulin Analog Premixes
Studies have shown that insulin analog premixes In addition, while the analog premixes can be given three times a day, RHI premixes cannot.
A study by Heise et al. showed that glucose infusion rates for BIAsp 30 approximated basal bolus with three injections [72] . Analog premixes may thus be a more effective choice than human premixes for some patients.
HIGH CONCENTRATION INSULIN
U-500 Regular Insulin
Severe insulin resistance is a condition in which a patient with diabetes requires more than 200 units of insulin daily. Obesity is one of the most common causes of insulin resistance [98] .
Severe insulin resistance is difficult to treat successfully, and to achieve good glycemic control 
INVESTIGATIONAL INSULINS AND THE FUTURE OF INSULIN THERAPY
The development of insulin analogs improved glycemic control and reduced nocturnal hypoglycemia, but further improvements are still necessary. While current basal insulin analogs have advantages over NPH, these analogs still do not have a completely flat profile, and do not achieve 24-hour insulin coverage in all patients [103] . Although hypoglycemia is reduced with insulin analog treatment, it remains an important limitation that can lead to increased food intake and decreased insulin dosage, with patients ultimately not meeting their fasting targets [104] .
Unrecognized hypoglycemia, including nocturnal hypoglycemia, can be particularly dangerous.
A major goal of investigational insulin therapies is to provide optimal basal insulin coverage that mimics the physiologic insulin secretion profile.
Flexibility and convenience in dosing regimens
and insulin administration techniques are also important factors to consider in the development of next-generation insulins.
Ultra-Long-Acting Basal Insulin
Insulin degludec, the only ultra-long-acting basal insulin, is currently in phase 3 development (Fig. 4 [50] ) [105] . The method of protraction involves the slow release of insulin degludec monomers from the multihexamers that only form after subcutaneous injection, resulting in an ultra-long duration of action over 42 hours, a long half-life (>24 hours), and a smooth and stable pharmacokinetic profile at steady state [104, 106] .
These multihexamers also provide a buffer against changes in absorption rate, which contributes to the stable and consistent pharmacokinetic profile [104] . The half-life of a drug is particularly with glargine [116] . In addition, LY treatment resulted in weight loss [117] .
Inhaled Insulin
Inhaled insulin delivery systems can provide hypoglycemia [118, 119] , it was pulled from the market due to poor uptake and acceptance by both patients and prescribers [120] .
The AER x insulin diabetes management system of Novo Nordisk Inc. generates insulin droplets for pulmonary delivery. A randomized trial found that AER x inhaled insulin was noninferior to subcutaneous insulin in lowering HbA 1c levels, but the AER x system was associated with a higher risk of nocturnal hypoglycemia [121] . Further investigations of AER x have been discontinued [120] .
Technosphere insulin (TI), another inhaled insulin, was compared in a randomized, open-label study to the efficacy and safety of subcutaneous RHI in covering prandial insulin needs. TI significantly improved PPG levels and had a more favorable PK/PD profile compared with subcutaneous RHI [122] . The TI system is currently undergoing phase 3 trials, and a placebo formulation has been developed for double-blind, placebo-controlled studies [120] .
Oral Insulin
Oral insulin can provide a convenient method of administration, potentially leading to improved glycemic control for patients with poor adherence to subcutaneous insulin regimens.
Physiological barriers of the gastrointestinal tract pose a major challenge for the optimal delivery of oral insulin [8] . Gut enzymes such as pepsin and trypsin break down insulin into its constituent amino acids, thereby abolishing insulin activity [8] . The tightly packed columnar cells and thick layer of mucin of the gastrointestinal tract create another barrier by preventing insulin absorption [8] . A major goal in the development of oral insulins is to bypass these natural defense mechanisms to allow for insulin entry into the gastrointestinal tract. 
Metabolic and Mitogenic Potential of Insulin Therapy
Insulin therapy is an important and, often, a lifesaving therapy for patients with diabetes. The molecular mechanisms by which insulin and hyperinsulinemia, whether in cell culture or in vivo lead to mitogenicity are caused by the ability of insulin to bind to insulin receptor and, to a much lesser degree, to bind to insulin-like growth factor 1 (IGF-1) receptor [136] . Therefore, enhanced cellular responsiveness to growth factors is a physiological effect of insulin.
This response becomes pathological in response to endogenous or exogenous hyperinsulinemia [142] . effect, but it can also change its mitogenic potency [143] . A study of patients without known malignant disease who had received first-time therapy for diabetes exclusively with human insulin, aspart, lispro or glargine was conducted to study the effect of these insulin products on neoplasms [143] . The study showed a positive association between cancer and insulin dose for all insulin types. Glargine had a dose-dependent increase in cancer risk compared with human insulin (P < 0.0001), whereas lispro and aspart did not show an increased risk of cancer [143] .
The relationships between insulin and cancer are not definitive and are often conflicting when a specific cancer and use of insulin were examined. Some studies have shown a positive correlation between insulin use and colorectal carcinoma [135, [144] [145] [146] , pancreatic cancer [147] , and liver cancer [148] . Other studies have shown no association between insulin therapy and pancreatic cancer [149] or prostate cancer [150] .
The ORIGIN study, however, the first long-term 
